ArticleBMC medicine2025
Prevalence and attributes of cervicovaginal human papillomavirus infection among a 35-year- age- cohort of ever-married women in a district of Sri Lanka: a cross-sectional study.
Article in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Associated risk factors and prevalence of human papillomavirus infection among females visiting tertiary care hospital: a cross-sectional study from Nepal.Open medicine (Warsaw, Poland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAll cervical cancers are virtually associated with sexually transmitted cervicovaginal human papillomavirus (HPV) infection. The objective of the study was to determine the prevalence and risk factors of cervicovaginal Human Papillomavirus infection among a 35-year-old-age cohort of ever-married women in Kalutara district.
methodsA community-based descriptive cross-sectional study was conducted from 1st of July 2018 to 30th November 2018 among ever-married women 35 years of age in Kalutara district. Three women from each cluster (n = 413) were selected by consecutive sampling technique. HPV/DNA cervical specimen collection (n = 822) was carried out. Cervical specimens were tested by well-trained cyto-screeners with cobas 4800 HPV/DNA automated Polymerase Chain Reaction (PCR) machine. An Interviewer-administered questionnaire was used to gather information regarding socio-demographics, reproductive health, contraceptive methods, and sexual behaviours. Multivariate logistic regression was performed and expressed as odds ratio (OR) and 95% confidence interval (CI).
resultsThe prevalence of HPV infection was 6.2% (95% CI: 6.18%-6.22%), while the prevalence of high-risk genotypes 16 and 18 was 1.94% (95% CI: 1.93%-1.95%). The prevalence of 12 pooled high-risk HPV infection was 4.14% (95% CI:4.13%-4.15%). In multivariate logistic regression analysis, age at marriage ≤ 24 years (OR = 4.04, 95% CI:1.75-9.34), any abortion including both induced and miscarriages (OR = 10.1, 95% CI: 3.07-33.7), use of hormonal contraceptives for ≥ 3 months (OR = 45.5, 95% CI: 18.7-110.5) and a number of vaginal deliveries > 2 (OR = 9.7, 95% CI: 3.7-25.2) were found to have a significant risk association with HPV infection, while average monthly income > Rs. 15,000 (OR = 0.12, 95% CI, 0.04-0.32) and ever use of a condom by a spouse (OR = 0.04, 95% CI: 0.01-0.16) were found to have a significant protective association with HPV infection.
conclusionsExposure to HPV infection is determined by risk factors such as early marriage, any abortions, prolonged usage of hormonal contraceptives, and high number of vaginal deliveries. Strengthening behaviour change communication to alleviate underlying risk factors and to promote prevention is very important.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.